Sixth Street Partners Management Company L P 13F Portfolio

The biggest buys make their thesis unambiguous: AI isn’t a theme; it’s the market’s new operating system, and they want equity claims on every layer of that stack.

• NVDA at 4.27% of the book is the fulcrum — the fund’s largest single bet on AI compute itself, taken with roughly a +23.8% mark‑to‑cost cushion, suggesting they were early and sized with intent rather than chasing late.
• AAPL at 3.90% and MSFT at 2.60% are sized like core equity infrastructure, not just growth names; both sit comfortably in the black (Apple roughly +14.0%, Microsoft +32.8% versus cost), reinforcing that the fund is content to ride these as long‑duration compounding machines.
• AMZN at 2.09% extends this into cloud and commerce rails, while the paired GOOGL and GOOG lines (together well north of 3% of the book) show they want full exposure to Alphabet’s AI‑monetization runway, not a token position.

Below the headline platforms, the rotation dives into semis that feed the build‑out: Micron, AMD, Broadcom, Texas Instruments, Intel, Qualcomm, Applied Materials, Lam Research and even SanDisk collectively represent a pronounced bet that memory, connectivity and equipment will participate meaningfully in AI capex, not just the GPU vendor.

At the same time, they make a deliberate call on broad equity factors via Schwab ETFs: FNDX, FNDF, FNDA, FNDE and SCHG together form a quasi‑index core around the stock picks, a way to keep factor exposure aligned with their macro view without diluting their concentrated AI and mega‑cap tilts.

The 13F only shows new positions this quarter; the biggest‑trims table is blank, so we can’t see explicit sells. But the pattern of what made the top‑50 tells you what they are deprioritizing.

First, they aren’t chasing small‑cap single names or speculative software. Outside the AI platforms and semis, the stock‑picking is almost exclusively in mature oligopolies: UnitedHealth, Eli Lilly, Merck, Amgen, Abbott, J&J, Bristol‑Myers; Coke and Pepsi; JPMorgan; the card networks Visa and Mastercard; Lockheed and Caterpillar. If there was ever a time to telegraph comfort with high‑beta cyclicals or early‑stage tech, this book doesn’t show it.

Second, even in sectors that could have been sized aggressively, they stay restrained. Tesla sits at just 1.08% despite being one of the few pure growth cyclicals in the portfolio and is actually underwater versus cost (around -12.2%), a signal they’re not reflexively averaging down into narrative stocks.

Finally, the reliance on Schwab bond‑like ETFs (SCHR, SMBS) and broad factor products as meaningful line items indicates that any trimming likely happened in more idiosyncratic, non‑core names that didn’t make this top‑50 cut. The capital freed up appears to have been redirected into scalable, liquid exposures rather than a new wave of stock‑specific punts.

With no prior‑quarter sector weights disclosed, we can’t quantify the rotation, but the current mix is loud enough. Technology at 45.35% is not “overweight tech”; it’s a structural bet that the equity risk premium will be earned through AI‑enabled platforms and the semis that power them.

Health care at 12.40% is the other anchor. The concentration in large‑cap pharma and biotech — Eli Lilly, Merck, Bristol‑Myers, Amgen, Abbott, J&J, plus UnitedHealth on the services side — reads like a deliberate choice to own regulated cash‑flow machines with real pricing power just as broader indices wrestle with margins and multiple compression.

Energy at 4.04% (Chevron, Exxon, ConocoPhillips) and industrials at 4.18% (Tesla, Lockheed Martin, Caterpillar) form the “hard assets and geopolitics” leg of the stool, a hedge against both inflation and global tension that can also participate if real‑asset scarcity becomes the next macro narrative.

Consumer exposure is split: discretionary and staples together sit in the high‑single digits, but the single‑name sizing in Home Depot, Walmart, Costco, Procter & Gamble, Coke and Pepsi is modest. They want the volume and brand resilience, not a grand statement about the consumer cycle.

Finally, the 13.89% chunk in unclassified Schwab and Berkshire holdings underscores the philosophy: use diversified vehicles to maintain broad beta and factor tilts, then layer concentrated tech and healthcare stock‑picks on top.

Put together, the book says Sixth Street believes the next leg of equity returns will be driven by AI platforms and the semiconductor ecosystem, but that the path will be noisy enough to require serious ballast. The chosen ballast is not cash; it’s durable oligopolies in healthcare, beverages, payments and energy, plus broad Schwab ETFs that keep the factor mix in check.

Given a three‑year weighted performance of -4.47% annualized, this looks like a fund that has felt the pain of being early or wrong on macro and is now anchoring its edge where its conviction is highest: foundational technology and pharma, supplemented rather than competed with by passive exposure. The relatively low top‑10 concentration of 21.8% reinforces that they want room to adjust around that core without creating a hostage position.

Going forward, expect any incremental risk to funnel into the same three lanes: AI infrastructure (more dollars into NVDA‑style and semi‑equipment names), healthcare innovation and services as a defensive grower, and real‑asset proxies in energy and defense. If the macro backdrop worsens, the Schwab ETFs, consumer staples and big‑pharma lines give them space to weather drawdowns without abandoning the AI thesis; if it improves, the technology stack they’ve built is positioned to capture the upside with leverage to both earnings and multiple expansion.